Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
6.1
3.6
Journals
Current Oncology
Special Issues
Emphasis on Cardiovascular Health from Cancer Therapy: Incidence, Mechanisms, and...
share announcement

Emphasis on Cardiovascular Health from Cancer Therapy: Incidence, Mechanisms, and Management

A special issue of Current Oncology (ISSN 1718-7729).

Deadline for manuscript submissions: 10 September 2026 | Viewed by 1226

Editor

Dr. Brijesh D. Patel

E-Mail Website
Guest Editor
Division of Cardiology, Indiana University School of Medicine, Indianapolis, IN 46074, USA
Interests: cardio-oncology; cardiovascular disease; cardiotoxicity; cardiovascular imaging

Special Issue Information

Dear Colleagues,

Cancer therapies have revolutionized survival outcomes, yet they pose significant risks to cardiovascular health. Treatment-related cardiac adverse effects include cardiomyopathy, arrhythmias, ischemic events, and vascular complications. Their incidence varies by therapeutic modality, with anthracyclines, HER2-targeted agents, immune checkpoint inhibitors, and thoracic radiation being major contributors. Understanding the underlying pathophysiology, ranging from oxidative stress and endothelial dysfunction to immune-mediated injury, is quintessential for developing preventive strategies.

This Special Issue provides a comprehensive overview of current evidence on the epidemiology and mechanisms of cardiotoxicity, highlighting advances in diagnostic imaging, biomarker-based surveillance, and risk stratification. It also addresses clinical management approaches, including cardioprotective interventions, optimization of cancer therapy, and multidisciplinary care models that integrate oncology and cardiology expertise. Emerging guidelines for long-term surveillance and novel therapeutic strategies are discussed to mitigate cardiovascular risk while preserving oncologic efficacy. By synthesizing recent research and clinical practice, this issue aims to enhance awareness and guide best practices in cardio-oncology, ultimately improving patient outcomes in an era of increasingly complex cancer care.

Dr. Brijesh D. Patel
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-anonymized peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardiotoxicity
  • cancer therapy-related cardiac dysfunction (CTRCD)
  • arrhythmia
  • cardiomyopathy
  • disparity
  • innovation
  • prevention

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1399 KB  
Article
Performance of Traditional Cardiovascular Risk Scores and Objective Optimization in Cancer Survivors
by Harsh A. Patel, Saifullah Syed, Pranathi Tella, Harshith Thyagaturu and Brijesh Patel
Curr. Oncol. 2026, 33(4), 230; https://doi.org/10.3390/curroncol33040230 - 19 Apr 2026
Viewed by 769
Abstract
Introduction: Cardiovascular disease (CVD) is a leading cause of non-cancer death among cancer survivors, attributable to cardiotoxic therapies and cardiovascular risk factors. General population risk prediction tools, including ASCVD (Atherosclerotic cardiovascular disease), Framingham’s Score, and PREVENT (Predicting Risk of Cardiovascular Disease EVENTS), lack [...] Read more.
Introduction: Cardiovascular disease (CVD) is a leading cause of non-cancer death among cancer survivors, attributable to cardiotoxic therapies and cardiovascular risk factors. General population risk prediction tools, including ASCVD (Atherosclerotic cardiovascular disease), Framingham’s Score, and PREVENT (Predicting Risk of Cardiovascular Disease EVENTS), lack cancer-specific variables. We evaluated whether these models, even after statistical optimization, could predict cardiovascular mortality in cancer survivors. Methods: Using the National Health and Nutrition Examination Survey (NHANES) 2001–2018, linked with National Death Index (NDI) mortality data, we conducted a retrospective analysis of 634 and 429 cancer survivors, respectively, across model-specific cohorts free of baseline cardiovascular disease. Discrimination was assessed for ASCVD, Framingham Score, and PREVENT using standardized thresholds of 7.5% and 20%, as well as Youden-optimized cutoffs. Area under the curve (AUC) comparisons were performed using the DeLong non-parametric method. Results: Standard thresholds showed suboptimal discrimination across all models (AUCs: ASCVD 0.56, Framingham 0.53, PREVENT 0.64). In contrast, Youden-optimized AUCs (ASCVD: 0.68; PREVENT: 0.71; all p < 0.001, DeLong test). Optimization increased the “low-risk” group’s mortality rate from 2.8% to 4.1% (RR = 1.47), suggesting improved statistical fit came at the cost of overestimating the risk. Optimized thresholds outperformed conventional cutoffs, underscoring the necessity for recalibrated, cohort-specific risk stratification in cancer survivors. Conclusions: Standard risk scores have inadequate discrimination for cardiovascular mortality prediction in cancer survivors. Threshold recalibration improves statistical metrics but does not resolve the structural failure of these models to account for cardiotoxic exposure. Development of cardio-oncology-specific risk models incorporating oncologic exposures is therefore warranted. Full article
(This article belongs to the Special Issue Emphasis on Cardiovascular Health from Cancer Therapy: Incidence, Mechanisms, and Management)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop